Enterprise Value
-14.79M
Cash
37.82M
Avg Qtr Burn
-10.8M
Short % of Float
0.13%
Insider Ownership
48.02%
Institutional Own.
8.61%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vebreltinib (APL-101) Details Non-small cell lung carcinoma | NDA FDA meeting | |
Uproleselan (APL-106) Details Acute myeloid leukemia | Phase 3 Data readout | |
Vebreltinib (APL-101) Details Glioblastoma | Phase 2 Update |